Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2003 Aug;74(8):1071–1079. doi: 10.1136/jnnp.74.8.1071

Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study

D Brooks 1, H Sagar 1
PMCID: PMC1738605  PMID: 12876237

Abstract

Objective: To study the effect of entacapone, a specific peripherally acting catechol-O-methyltransferase (COMT) inhibitor used in combination with levodopa treatment, in cases of Parkinson's disease with both fluctuating and non-fluctuating response to treatment.

Methods: A randomised, placebo controlled, double blind, six month study was undertaken in 172 fluctuating and 128 non-fluctuating patients. The clinical efficacy and safety of 200 mg entacapone given with each daily levodopa dose was studied. Efficacy was examined using home diaries, the unified Parkinson disease rating scale (UPDRS), and recording of daily levodopa dose.

Results: The primary efficacy variable for fluctuating patients—the proportion of daily ON time—showed a significant increase compared with placebo (p < 0.05). The absolute ON time (mean (SD)) increased from 9.5 (2.5) to 10.8 (2.4) hours (p < 0.01), and the daily OFF time was correspondingly reduced from 7.0 (2.6) to 5.9 (2.5) hours (p < 0.05 v placebo). This improvement was achieved despite a reduction in daily levodopa requirements. The effect was rapidly lost on withdrawal of entacapone. In non-fluctuating patients, the primary efficacy measure was part II of the UPDRS (activities of daily living; ADL). In this group of patients, ADL scores improved in the entacapone group (p < 0.01 v placebo), and there was also a 40 mg reduction in levodopa requirement (p < 0.01 v placebo). Entacapone was well tolerated by both fluctuating and non-fluctuating patients.

Conclusions: The ability of entacapone to provide additional benefits to levodopa treatment in increasing ON time in fluctuating Parkinson's disease patients was confirmed. A novel finding was that patients without fluctuations also obtained benefit from the addition of entacapone to their levodopa treatment, as evidenced by improved ADL scores and a relatively reduced levodopa requirement.

Full Text

The Full Text of this article is available as a PDF (230.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adler C. H., Singer C., O'Brien C., Hauser R. A., Lew M. F., Marek K. L., Dorflinger E., Pedder S., Deptula D., Yoo K. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III. Arch Neurol. 1998 Aug;55(8):1089–1095. doi: 10.1001/archneur.55.8.1089. [DOI] [PubMed] [Google Scholar]
  2. Agid Y., Ahlskog E., Albanese A., Calne D., Chase T., De Yebenes J., Factor S., Fahn S., Gershanik O., Goetz C. Levodopa in the treatment of Parkinson's disease: a consensus meeting. Mov Disord. 1999 Nov;14(6):911–913. doi: 10.1002/1531-8257(199911)14:6<911::aid-mds1001>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  3. Baas H., Beiske A. G., Ghika J., Jackson M., Oertel W. H., Poewe W., Ransmayr G. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry. 1997 Oct;63(4):421–428. doi: 10.1136/jnnp.63.4.421. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Baas H., Zehrden F., Selzer R., Kohnen R., Loetsch J., Harder S. Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease. Clin Pharmacokinet. 2001;40(5):383–393. doi: 10.2165/00003088-200140050-00005. [DOI] [PubMed] [Google Scholar]
  5. Bonifati V., Meco G. New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease. Pharmacol Ther. 1999 Jan;81(1):1–36. doi: 10.1016/s0163-7258(98)00032-1. [DOI] [PubMed] [Google Scholar]
  6. Durif F., Devaux I., Pere J. J., Delumeau J. C., Bourdeix I., F-01 Study Group Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: an open, multicenter study. Eur Neurol. 2001;45(2):111–118. doi: 10.1159/000052104. [DOI] [PubMed] [Google Scholar]
  7. Hobson J. P., Edwards N. I., Meara R. J. The Parkinson's Disease Activities of Daily Living Scale: a new simple and brief subjective measure of disability in Parkinson's disease. Clin Rehabil. 2001 Jun;15(3):241–246. doi: 10.1191/026921501666767060. [DOI] [PubMed] [Google Scholar]
  8. Jenkinson C., Fitzpatrick R., Peto V. Health-related quality-of-life measurement in patients with Parkinson's disease. Pharmacoeconomics. 1999 Feb;15(2):157–165. doi: 10.2165/00019053-199915020-00004. [DOI] [PubMed] [Google Scholar]
  9. Kaakkola S. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs. 2000 Jun;59(6):1233–1250. doi: 10.2165/00003495-200059060-00004. [DOI] [PubMed] [Google Scholar]
  10. Kaakkola S., Gordin A., Männistö P. T. General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase. Gen Pharmacol. 1994 Sep;25(5):813–824. doi: 10.1016/0306-3623(94)90082-5. [DOI] [PubMed] [Google Scholar]
  11. Karlsen K. H., Tandberg E., Arsland D., Larsen J. P. Health related quality of life in Parkinson's disease: a prospective longitudinal study. J Neurol Neurosurg Psychiatry. 2000 Nov;69(5):584–589. doi: 10.1136/jnnp.69.5.584. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Keränen T., Gordin A., Harjola V. P., Karlsson M., Korpela K., Pentikäinen P. J., Rita H., Seppälä L., Wikberg T. The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol. 1993 Apr;16(2):145–156. doi: 10.1097/00002826-199304000-00007. [DOI] [PubMed] [Google Scholar]
  13. Koller W. C., Hutton J. T., Tolosa E., Capilldeo R. Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology. 1999 Sep 22;53(5):1012–1019. doi: 10.1212/wnl.53.5.1012. [DOI] [PubMed] [Google Scholar]
  14. Kurth M. C., Adler C. H., Hilaire M. S., Singer C., Waters C., LeWitt P., Chernik D. A., Dorflinger E. E., Yoo K. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. Neurology. 1997 Jan;48(1):81–87. doi: 10.1212/wnl.48.1.81. [DOI] [PubMed] [Google Scholar]
  15. Larsen J. P., Karlsen K., Tandberg E. Clinical problems in non-fluctuating patients with Parkinson's disease: a community-based study. Mov Disord. 2000 Sep;15(5):826–829. doi: 10.1002/1531-8257(200009)15:5<826::aid-mds1010>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  16. Marsden C. D., Parkes J. D. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet. 1976 Feb 7;1(7954):292–296. doi: 10.1016/s0140-6736(76)91416-1. [DOI] [PubMed] [Google Scholar]
  17. Merello M., Lees A. J., Webster R., Bovingdon M., Gordin A. Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 1994 Feb;57(2):186–189. doi: 10.1136/jnnp.57.2.186. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Myllylä V. V., Kultalahti E. R., Haapaniemi H., Leinonen M., FILOMEN Study Group Twelve-month safety of entacapone in patients with Parkinson's disease. Eur J Neurol. 2001 Jan;8(1):53–60. doi: 10.1046/j.1468-1331.2001.00168.x. [DOI] [PubMed] [Google Scholar]
  19. Nissinen E., Lindén I. B., Schultz E., Pohto P. Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone. Naunyn Schmiedebergs Arch Pharmacol. 1992 Sep;346(3):262–266. doi: 10.1007/BF00173538. [DOI] [PubMed] [Google Scholar]
  20. Nutt J. G. Catechol-O-methyltransferase inhibitors for treatment of Parkinson's disease. Lancet. 1998 Apr 25;351(9111):1221–1222. doi: 10.1016/S0140-6736(05)79311-9. [DOI] [PubMed] [Google Scholar]
  21. Nutt J. G., Holford N. H. The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Ann Neurol. 1996 May;39(5):561–573. doi: 10.1002/ana.410390504. [DOI] [PubMed] [Google Scholar]
  22. Nutt J. G., Woodward W. R., Beckner R. M., Stone C. K., Berggren K., Carter J. H., Gancher S. T., Hammerstad J. P., Gordin A. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology. 1994 May;44(5):913–919. doi: 10.1212/wnl.44.5.913. [DOI] [PubMed] [Google Scholar]
  23. Pahwa R., Lyons K., McGuire D., Silverstein P., Zwiebel F., Robischon M., Koller W. C. Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures. Mov Disord. 1997 Sep;12(5):677–681. doi: 10.1002/mds.870120508. [DOI] [PubMed] [Google Scholar]
  24. Piccini P., Brooks D. J., Korpela K., Pavese N., Karlsson M., Gordin A. The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2000 May;68(5):589–594. doi: 10.1136/jnnp.68.5.589. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Rajput A. H., Martin W., Saint-Hilaire M. H., Dorflinger E., Pedder S. Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology. 1997 Oct;49(4):1066–1071. doi: 10.1212/wnl.49.4.1066. [DOI] [PubMed] [Google Scholar]
  26. Rinne U. K., Larsen J. P., Siden A., Worm-Petersen J. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology. 1998 Nov;51(5):1309–1314. doi: 10.1212/wnl.51.5.1309. [DOI] [PubMed] [Google Scholar]
  27. Ruottinen H. M., Rinne U. K. A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease. Clin Neuropharmacol. 1996 Aug;19(4):283–296. doi: 10.1097/00002826-199619040-00001. [DOI] [PubMed] [Google Scholar]
  28. Ruottinen H. M., Rinne U. K. Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. Clin Neuropharmacol. 1996 Jun;19(3):222–233. doi: 10.1097/00002826-199619030-00004. [DOI] [PubMed] [Google Scholar]
  29. Ruottinen H. M., Rinne U. K. Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. J Neurol Neurosurg Psychiatry. 1996 Jan;60(1):36–40. doi: 10.1136/jnnp.60.1.36. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Suchowersky O., Bailey P., Pourcher E., Bulger L., Facciponte G. Comparison of two dosages of tolcapone added to levodopa in nonfluctuating patients with PD. Clin Neuropharmacol. 2001 Jul-Aug;24(4):214–220. doi: 10.1097/00002826-200107000-00004. [DOI] [PubMed] [Google Scholar]
  31. Waters C. H., Kurth M., Bailey P., Shulman L. M., LeWitt P., Dorflinger E., Deptula D., Pedder S. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study Group. Neurology. 1997 Sep;49(3):665–671. doi: 10.1212/wnl.49.3.665. [DOI] [PubMed] [Google Scholar]
  32. Waters C. Catechol-O-methyltransferase (COMT) inhibitors in Parkinson's disease. J Am Geriatr Soc. 2000 Jun;48(6):692–698. doi: 10.1111/j.1532-5415.2000.tb04732.x. [DOI] [PubMed] [Google Scholar]
  33. Yeh K. C., August T. F., Bush D. F., Lasseter K. C., Musson D. G., Schwartz S., Smith M. E., Titus D. C. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. Neurology. 1989 Nov;39(11 Suppl 2):25–38. [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES